# US 2010/0028860 A1 · Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0028860 A1
- Document ID: US20100028860A1
- Status: Published application
- Kind: A1
- Application number: 12/548,597
- Filed: 2009-08-27
- Published: 2010-02-04
- Earliest claimed: 2004-09-21
- Assignees: Boehringer Ingelheim Vetmedica GmbH
- Inventors: Michael Roof; Eric Vaughn; Wesley Johnson
- Web page: https://patentgrep.com/patent/US20100028860A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2770/10031: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of predicting the virulence of a new or uncharacterized PRRS virus strain is provided wherein the strain is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus strain of known virulence, as a measure of the virulence of the new or uncharacterized strain.

## Claims

### Claim 1

A method of predicting the virulence of a PRRS virus strain of unknown virulence, comprising the steps of administering a quantity of said PRRS virus strain into PRRS-free swine, allowing the virus to replicate in said swine for a period of from about 3-15 days, measuring the rate of virus growth and/or the magnitude of viremia during said period, and comparing said rate of growth or viremia magnitude with the rate of growth and/or viremia magnitude of a PRRS virus strain of known virulence as a predictor of virulence of PRRS strain of unknown virulence.

### Claim 2 (depends on 1)

The method of claim 1, said period being between from about 3 to 7 days.

### Claim 3 (depends on 1)

The method of claim 1, including the step of measuring the magnitude of viremia during said period, and comparing such magnitude with the viremia magnitude of said known PRRS virus strain.

### Claim 4 (depends on 1)

The method of claim 1, said quantity of administered virus being similar to the amount an animal would receive by natural exposure.

### Claim 5 (depends on 1)

The method of claim 1, said PRRS virus being adminstered by a method selected from the group consisting of oral, intranasal, intramuscular, intra-lymph node, intradermal, intraperitoneal, subcutaneous, and combinations thereof.

### Claim 6 (depends on 1)

The method of claim 1, said rate of growth or viremia magnitude being measured in a biological sample from said swine.

### Claim 7 (depends on 1)

The method of claim 1, said viremia being measured by Log10 TCID50/ml, reverse transcriptase-polymerase chain reaction, PRRS specific ELISA, PRRS protein-specific ELISA, and combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, further including the step of observing said swine for clinical signs of PRRS infection after administration of said PRRS strain.

### Claim 9 (depends on 8)

The method of claim 8, said clinical signs including respiratory signs, behavior, coughing, and combinations thereof.

### Claim 10 (depends on 1)

The method of claim 1, further including the step of predicting that the PRRS strain will be of high virulence when its rate of growth or viremia magnitude are similar to that of a strain with high virulence.

### Claim 11 (depends on 1)

The method of claim 1, further including the step of predicting that the PRRS strain will be of low virulence when its rate of growth or viremia magnitude are similar to that of a strain of low virulence.

### Claim 12 (depends on 1)

The method of claim 1, said administered amount of PRRS virus being up to about 5 ml of inocula having a viral concentration of up to 5.0 Log10 TCID50/ml.